Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates

分组1 - Biogen Inc. reported quarterly earnings of $1.99 per share, exceeding the Zacks Consensus Estimate of $1.61 per share, but down from $3.44 per share a year ago, representing an earnings surprise of +23.40% [1] - The company posted revenues of $2.28 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.06%, compared to $2.45 billion in revenues a year ago [2] - Biogen has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Biogen shares up about 5.3% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] - The current consensus EPS estimate for the coming quarter is $3.48 on revenues of $2.28 billion, and for the current fiscal year, it is $14.84 on revenues of $9.32 billion [7] - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently in the top 37% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]